Complete pathological response has been recognised as an important predictor of long-term remission, meaning it is often a key endpoint in clinical trials. Dr Bernardo Rapoport talks to touchONCOLOGY about complete pathological response and which clinical characteristics, such as molecular subtype and Ki-67, are associated with pathological response. Ki-67 is an important prognostic factor, not only in breast cancer but also in neoendocrine tumours, prostate cancer, and brain tumours. Dr Rapoport explains how the expression of Ki-67 translates to cell replication and how it can be an indicator of treatment response.
1. What is the definition of complete pathological response? (0:11)
2. Why has complete pathological response become such an important endpoint in trials of neoadjuvant chemotherapy in early breast cancer? (1:09)
3. What were the most important prognostic factors associated with complete pathological response in your recent study? (2:03)
4. What is the Ki-67 protein and what is its prognostic significance in early breast cancer subtypes? (3:09)
5. What future studies are planned in the investigation of this potential biomarker? (4:30)
Speaker disclosures: Bernardo Rapoport has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018.
Share this Video
Related Videos In Breast Cancer
Angela DeMichele, ASCO 2023: The PALLAS trial, palbociclib with adjuvant endocrine therapy in patients with stage II-III breast cancer
The PALLAS trial assessed the efficacy of adding palbociclib to adjuvant endocrine therapy in patients with stage II-III breast cancer. In this touchONCOLOGY interview, we speak with Dr Angela DeMichele (Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA) to discuss the PALLAS trial and how it compares to the other CDK4/6 inhibitor adjuvant trials, […]
Sara Tolaney, ASCO 2023: Highlights from the NATALEE trial of ribociclib and endocrine therapy in the treatment of breast cancer
touchONCOLOGY spoke with editorial board member Sara Tolaney (Dana-Farber Cancer Institute, Boston, MA, USA) to discuss her highlights from the ASCO annual meeting. She highlights data from the NATALEE study (NCT03701334), which met its primary endpoint at interim analysis, thus showing clinically meaningful benefit for patients with early breast cancer. The abstract entitled ‘Ribociclib and […]
Sara Tolaney, ASCO 2023: Primary outcome analysis of the phase 3 SONIA trial and the final overall survival results from the phase 3 TROPiCS-02 study
touchONCOLOGY spoke with editorial board member Sara Tolaney (Dana-Farber Cancer Institute, Boston, MA, USA) to discuss her highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting, 2–6, June 2023. These include the phase 3 SONIA trial (NCT03425838) assessing CDK4/6 inhibitors for patients with HR+, HER2- advanced breast cancer, and the final overall survival […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!